WO1997034931A1 - Anticorps specifique de staphylococcus aureus et utilisations - Google Patents
Anticorps specifique de staphylococcus aureus et utilisations Download PDFInfo
- Publication number
- WO1997034931A1 WO1997034931A1 PCT/FR1997/000510 FR9700510W WO9734931A1 WO 1997034931 A1 WO1997034931 A1 WO 1997034931A1 FR 9700510 W FR9700510 W FR 9700510W WO 9734931 A1 WO9734931 A1 WO 9734931A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- staphylococcus aureus
- antibody
- type
- fibrinogen
- reagent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
Definitions
- the present invention relates to the field of detection of Staphylococcus aureus bacteria, and in particular strains of Staphylococcus aureus which are resistant to methicillin.
- detection is understood collectively all the techniques making it possible to identify, qualitatively and / or quantitatively, or to enrich, purify or separate a biological analyte, in this case bacteria
- a reagent for detecting Staphylococcus aureus bacteria, including strains resistant to methicillin, this reagent comprising:
- an antibody, monoclonal or polyclonal, which specifically recognizes an epitope is brought to the strains of Staphylococcus aureus of different capsular serotypes, in particular strains resistant to methicillin.
- This antibody is chosen from type G immunoglobulins, type M immunoglobulins and type A immunoglobulins.
- a particularly advantageous application of the antibody according to the invention consists in incorporating it into a specific reagent for the detection of Staphylococcus aureus, including strains resistant to methicillin.
- the sensitivity of the reagent of the invention is higher, since the capacity for recognition of capsular serotypes is greater.
- a monoclonal or polyclonal antibody specific for an epitope common to strains of Staphylococcus aureus of different capsular serotypes, in particular strains resistant to methicillin, said antibody being chosen from immunoglobulins of the type G, type M immunoglobulins and type A immunoglobulins; this antibody recognizes both specifically at least two different capsular serotypes of said strains of Staphylococcus aureus; preferably, it is chosen from type G immunoglobulins and type M immunoglobulins;
- a monoclonal or polyclonal antibody as defined above which in particular recognizes at least the capsular serotype of type 5 and the capsular serotype of type 8 of said strains of Staphylococcus aureus, a monoclonal antibody capable of being obtained according to a technique suitable for Galfe et al.
- the myeloma line SP2 / 0-Agl4 (ATCC CRL 1581); the fusion is carried out with spleen cells of mice of the BALB / C species and of the BALB / CBYJICO strain (marketed by the company IFFA Credo), immunized with a strain of Staphylococcus aureus type 5, according to conventional techniques; the clones obtained were screened by immunoenzymatic techniques (ELISA); the selected clones were reinjected intraperitoneally into mice prepared beforehand for the production of ascites fluid; each monoclonal antibody was used to sensitize latex particles and was tested for its specificity in recognizing the capsular polysaccharides of Staphylococcus aureus; the monoclonal antibodies called P2G7A1E5 and P6D8D12E1 respectively were chosen because of their specificity in recognizing a common epitope with different capsular
- hybridoma cell line such as that deposited under No. 96021514, on 02/15/1996 with ECACC, or such as that deposited under No. 96021513, on 02/15/1996 with ECACC , or any other hybridoma cell line derived, for example any offspring of this line;
- the cell lines are claimed as such, as well as any derived cell line, that is to say capable of producing antibodies having the same immunological characteristics as those described in the present invention
- a specific reagent for detecting Staphylococcus aureus bacteria and in particular strains resistant to methicillin comprising at least one antibody specifically recognizing at least one common epitope of the various capsular serotypes of Staphylococcus aureus strains resistant to methicillin, said reagent comprising at least a monoclonal or polyclonal antibody as defined above; said antibody can be fixed or coupled, or not, on a support or a marker; the term “monoclonal or polyclonal antibody” means the antibodies as defined above as well as any antibody having cross-specificity with them; - a specific reagent, in particular for detecting Staphylococcus aureus bacteria and in particular strains resistant to methicillin, further comprising fibrinogen or a fibrinogen-based compound capable of being recognized by the affinity factor for fibrinogen of Staphylococcus aureus ; the fibrinogen or fibrinogen compound can be fixed or coupled, or not, on a support or on a marker;
- a specific reagent in particular for detecting Staphylococcus aureus bacteria and in particular strains resistant to methicillin, further comprising immunoglobulins or their Fc fragment recognized by protein A of Staphylococcus aureus, fixed or coupled, or not, on a support or on a marker, all kinds of support or marker can be envisaged according to the invention.
- suspended particles are in particular latex particles, such as polystyrene beads or similar particles, preferably having a size of less than 2 ⁇ m.
- latex particles such as polystyrene beads or similar particles, preferably having a size of less than 2 ⁇ m.
- Estapor particles sold by the company RHONE-POULENC, such as:
- - polystyrene particles having carboxylic groups PSI 480, having a diameter of 0.8 ⁇ m.
- Magnetic gels can also be used, such as polyacrylamide and / or agarose gels containing magnetic particles.
- gels such as Ultrogel and Magnogel (trademarks) from the company IBF can be used.
- the support used in a reagent according to the present invention can also be red cells, for example from sheep.
- the support may be in the form of a plate, a cone, a strip, for example of polystyrene, or a styrene-based copolymer, a glass tube or the like.
- the fixation being able to be spontaneous, during an incubation of the latex particles in a solution containing the antibodies and the fibrinogen; an incubation for example of approximately 2 hours at 20 ° C is often sufficient;
- the fixing being able to be carried out by creating a covalent bond between the antibodies and the reactive groups present on certain particles of the latex; it is possible for example to use a carbodiimide to create the covalent bond.
- the support consists of red blood cells
- these can be sensitized beforehand by fibrinogen or any other suitable molecule, according to conventional techniques.
- concentration of antibodies to be fixed on the latex particles which must be determined for each antibody according to known methods, is usually between 0.1 ⁇ g and 100 ⁇ g of antibody proteins per milliliter of latex in solution.
- the antibodies and the fibrinogen can be fixed on a single suspension of particles, for example of latex, or else can be fixed on suspensions of respectively different particles, such as red blood cells and latex particles, or different latexes which are then mixed to form the reagent.
- the marker can be any biological or chemical molecule, for example an enzyme, a hapten, an oligonucleotide, a radioactive element, etc.
- reagent as defined above comprising an antibody of the immunoglobulin type comprising an Fc fragment capable of binding to protein A of Staphylococcus aureus and / or another compound based on fibrinogen or derivative, capable of reacting with the affinity factor for the fibrinogen of said bacteria, said reagent further comprising at least one polyclonal or monoclonal antibody capable of specifically recognizing different capsular serotypes of Staphylococcus aureus, in particular serotypes type 5 and 8;
- EXAMPLE 1 Composition of a reagent according to the invention, called SLIDEX 5 ⁇ PH PLUS
- the reagent comprises an antibody of the immunoglobulin type comprising an Fc fragment capable of binding to the protein A of Staphylococcus aureus and / or another compound based on fibrinogen or derivative, capable of reacting with the affinity factor for fibrinogen of said bacteria , said reagent comprising in addition, at least one polyclonal or monoclonal antibody capable of specifically recognizing different capsular serotypes of Staphylococcus aureus, in particular serotypes of type 5 and 8.
- EXAMPLE 2 Process for obtaining the antibody contained in the reagent of Example 1
- Culture medium Columbia agar + 5% sheep blood.
- the strains stored at -80 ° C are cultured twice on sheep blood agar.
- the colonies are suspended in physiological saline at a concentration of 3 ⁇ 10 9 germs / ml.
- Vaccines are prepared immediately.
- Immunization animal female mice of the BALB / C species and of the BALB / CBYJICO strain (supplied by
- insulin (5 ⁇ g / l), 2-mercaptoethanol (10 ⁇ M), ethanolamine (20 ⁇ M), penicillin (100 U / ml), streptomycin (50 ⁇ g / ml).
- Subculture technique the cells are subcultured every 2 or 3 days.
- IMDM IMDM added with 10% of FCS and 10% of DMSO (dimethyl sulfoxide - Sigma)
- the cell suspension is centrifuged at 200 g, 10 minutes, 25 ° C.
- the cells are resuspended in NaCl 9% at a rate of IO 6 cells / ml,
- Pasteur diagnosis ref. 56356 lot 4L042R (exp 2/96) and lot SE 047 R (exp. 7/96),
- the strains were grown on Columbia agar + 5% sheep blood.
- inint means "uninterpretable" In accordance with this table, all of the strains have been detected, which gives a sensitivity of 100% for each of the reagents.
- S species. epidermidis, S. simulans, S. hyicus may have a capsule.
- S species. lugdunen ⁇ is, S. schleiferi, S. hyicus, S. intermedius may include the affinity factor for fibrinogen.
- PASTOREX STAPH PLUS and STAPHAUREX are identical (88.44%) but lower than those of STAPHYSLIDE (91.37%) and SLIDEX STAPH PLUS (92.57%).
- Table 5 shows the sensitivity and specificity results for each of the reagents.
- meti R meti S
- meti S mean "resistant to methicillin” and “sensitive to methicillin” respectively.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97915542A EP0827512B1 (fr) | 1996-03-21 | 1997-03-21 | Anticorps specifique de staphylococcus aureus et utilisations |
US08/952,052 US6340571B1 (en) | 1996-03-21 | 1997-03-21 | Antibodies specific for Staphylococcus aureus, and use thereof |
JP53321297A JP4213213B2 (ja) | 1996-03-21 | 1997-03-21 | 黄色ブドウ球菌に特異的な抗体及びその使用 |
DE69718261T DE69718261T2 (de) | 1996-03-21 | 1997-03-21 | Für staphylococcus aureus spezifischer antikörper und seine verwendung |
CA2221893A CA2221893C (fr) | 1996-03-21 | 1997-03-21 | Anticorps specifique de staphylococcus aureus et utilisations |
AT97915542T ATE230760T1 (de) | 1996-03-21 | 1997-03-21 | Für staphylococcus aureus spezifischer antikörper und seine verwendung |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR96/03761 | 1996-03-21 | ||
FR9603761A FR2746398B1 (fr) | 1996-03-21 | 1996-03-21 | Anticorps specifique de staphylococcus aureaus, et utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997034931A1 true WO1997034931A1 (fr) | 1997-09-25 |
Family
ID=9490562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1997/000510 WO1997034931A1 (fr) | 1996-03-21 | 1997-03-21 | Anticorps specifique de staphylococcus aureus et utilisations |
Country Status (10)
Country | Link |
---|---|
US (1) | US6340571B1 (fr) |
EP (1) | EP0827512B1 (fr) |
JP (1) | JP4213213B2 (fr) |
AT (1) | ATE230760T1 (fr) |
CA (1) | CA2221893C (fr) |
DE (1) | DE69718261T2 (fr) |
ES (1) | ES2188927T3 (fr) |
FR (1) | FR2746398B1 (fr) |
PT (1) | PT827512E (fr) |
WO (1) | WO1997034931A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055218A1 (fr) * | 2000-01-31 | 2001-08-02 | The Procter & Gamble Company | Anticorps diriges contre la proteine multiresistante staphylococcique |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1173485A1 (fr) * | 1999-05-03 | 2002-01-23 | Medarex, Inc. | Anticorps humains diriges contre le staphylococcus aureus |
EP1695086B1 (fr) * | 2003-12-09 | 2009-02-18 | BioMerieux, Inc. | Techniques de detection de pathogenes bacteriens |
WO2005068647A2 (fr) * | 2003-12-09 | 2005-07-28 | Biomerieux, Inc. | Procedes de detection de pathogenes bacteriens |
US20100047252A1 (en) * | 2006-11-22 | 2010-02-25 | 3M Innovative Properties Company | Antibody with protein a selectivity |
US7488807B2 (en) * | 2006-11-22 | 2009-02-10 | 3M Innovative Properties Company | Antibody with protein A selectivity |
WO2009091983A1 (fr) * | 2008-01-18 | 2009-07-23 | 3M Innovative Properties Company | Procédés de détection d'un analyte |
PL2396036T3 (pl) | 2009-02-13 | 2017-12-29 | Immunomedics, Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
PL2414387T3 (pl) | 2009-04-03 | 2016-06-30 | Univ Chicago | Kompozycje i sposoby związane z wariantami białka A (SpA) |
ES2537437T3 (es) * | 2009-05-18 | 2015-06-08 | Julius-Maximilians-Universität Würzburg | Anticuerpos o fragmentos de éstos dirigidos contra un epítopo del Staphylococcus aureus de IsaA o IsaB |
EP3009455A1 (fr) | 2009-09-16 | 2016-04-20 | Immunomedics Inc. | Anticorps anti-cea de classe i et leurs utilisations |
WO2011068845A1 (fr) | 2009-12-02 | 2011-06-09 | Immunomedics, Inc. | Combinaison de radioimmunotherapie et conjugues anticorps-medicament pour une meilleure therapie du cancer |
KR20130093084A (ko) | 2010-07-02 | 2013-08-21 | 더 유니버시티 오브 시카고 | 단백질 A(SpA) 변이체와 관련된 조성물 및 방법 |
JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
WO2014028560A2 (fr) | 2012-08-14 | 2014-02-20 | Ibc Pharmaceuticals, Inc. | Anticorps bispécifiques redirigés contre des cellules t pour le traitement de maladies |
EP2900277B1 (fr) | 2012-12-13 | 2022-02-16 | Immunomedics, Inc. | Dosages d'immuno-conjugués d'anticorps et de sn-38 pour améliorer l'efficacité et réduire la toxicité |
CA2937236C (fr) | 2014-02-21 | 2023-03-07 | Ibc Pharmaceuticals, Inc. | Traitement d'une maladie par induction d'une reponse immune a des cellules exprimant le trop-2 |
CN106029098A (zh) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
CA2953567C (fr) | 2014-06-24 | 2023-09-05 | Immunomedics, Inc. | Therapie par anti-histone pour necrose vasculaire dans la glomerulonephrite severe |
JP6678941B2 (ja) | 2014-10-07 | 2020-04-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗体−薬物コンジュゲートのネオアジュバント使用 |
JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け |
PL3313443T3 (pl) | 2015-06-25 | 2023-11-06 | Immunomedics, Inc. | Łączenie przeciwciał anty-hla-dr lub anty-trop-2 z inhibitorami mikrotubuli, inhibitorami parp, 5 inhibitorami kinazy brutona lub inhibitorami 3-kinazy fosfoinozytydu istotnie poprawia wynik terapeutyczny nowotworu |
SI3316885T1 (sl) | 2015-07-01 | 2021-09-30 | Immunomedics, Inc. | Imunokonjugati protitelo-SN-38 z linkerjem CL2A |
JPWO2022239720A1 (fr) | 2021-05-10 | 2022-11-17 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0323331A1 (fr) * | 1987-12-24 | 1989-07-05 | Institut Pasteur | Réactif pour la détection de Staphylococcus aureus par agglutination |
WO1990015077A1 (fr) * | 1989-06-01 | 1990-12-13 | The Gillette Company | Anticorps monoclonal specifique des proteines de transport bacterien, et composition desodorisante contenant des anticorps |
FR2679923A1 (fr) * | 1991-08-02 | 1993-02-05 | Bio Merieux | Reactif d'identification des bacteries de l'espece staphyloccocus aureus. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1231067A (fr) * | 1983-08-16 | 1988-01-05 | Bioclones (Proprietary) Limited | Anticorps monoclonal contre la peroxydase et hybridome producteur |
US5242824A (en) * | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
-
1996
- 1996-03-21 FR FR9603761A patent/FR2746398B1/fr not_active Expired - Fee Related
-
1997
- 1997-03-21 US US08/952,052 patent/US6340571B1/en not_active Expired - Lifetime
- 1997-03-21 WO PCT/FR1997/000510 patent/WO1997034931A1/fr active IP Right Grant
- 1997-03-21 DE DE69718261T patent/DE69718261T2/de not_active Expired - Lifetime
- 1997-03-21 EP EP97915542A patent/EP0827512B1/fr not_active Expired - Lifetime
- 1997-03-21 AT AT97915542T patent/ATE230760T1/de active
- 1997-03-21 PT PT97915542T patent/PT827512E/pt unknown
- 1997-03-21 ES ES97915542T patent/ES2188927T3/es not_active Expired - Lifetime
- 1997-03-21 JP JP53321297A patent/JP4213213B2/ja not_active Expired - Lifetime
- 1997-03-21 CA CA2221893A patent/CA2221893C/fr not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0323331A1 (fr) * | 1987-12-24 | 1989-07-05 | Institut Pasteur | Réactif pour la détection de Staphylococcus aureus par agglutination |
WO1990015077A1 (fr) * | 1989-06-01 | 1990-12-13 | The Gillette Company | Anticorps monoclonal specifique des proteines de transport bacterien, et composition desodorisante contenant des anticorps |
FR2679923A1 (fr) * | 1991-08-02 | 1993-02-05 | Bio Merieux | Reactif d'identification des bacteries de l'espece staphyloccocus aureus. |
Non-Patent Citations (2)
Title |
---|
CROIZE J ET AL: "IMPROVED IDENTIFICATION OF STAPHYLOCOCCUS - AUREUS USING A NEW AGGLUTINATION TEST RESULTS OF AN INTERNATIONAL STUDY.", APMIS 101 (6). 1993. 487-491, XP000612057 * |
FELTEN A ET AL: "Review of slide agglutination tests, Pastorex Staph Plus, Slidex Staph-kit and Staph aureus, in the rapid detection of Staphylococcus aureus in clinic isolates.", PATHOLOGIE BIOLOGIE 43 (5). 1995. 471-476, XP002020325 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055218A1 (fr) * | 2000-01-31 | 2001-08-02 | The Procter & Gamble Company | Anticorps diriges contre la proteine multiresistante staphylococcique |
Also Published As
Publication number | Publication date |
---|---|
JPH11506026A (ja) | 1999-06-02 |
ATE230760T1 (de) | 2003-01-15 |
EP0827512A1 (fr) | 1998-03-11 |
JP4213213B2 (ja) | 2009-01-21 |
EP0827512B1 (fr) | 2003-01-08 |
ES2188927T3 (es) | 2003-07-01 |
DE69718261T2 (de) | 2003-09-04 |
CA2221893C (fr) | 2011-05-03 |
US6340571B1 (en) | 2002-01-22 |
FR2746398B1 (fr) | 1998-04-30 |
PT827512E (pt) | 2003-04-30 |
DE69718261D1 (de) | 2003-02-13 |
FR2746398A1 (fr) | 1997-09-26 |
CA2221893A1 (fr) | 1997-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0827512B1 (fr) | Anticorps specifique de staphylococcus aureus et utilisations | |
JPH052318B2 (fr) | ||
JPH03236794A (ja) | ヒトモノクローン抗体の製造法 | |
JPS62187417A (ja) | 緑膿菌血清型に対する交さ反応性かつ交さ防御性単クロ−ン性抗体 | |
JPH02500004A (ja) | 非還元・非酵素的糖鎖形成蛋白に対するモノクローナル抗体 | |
JPH029366A (ja) | モノクローナル二特異的免疫グロブリンを製造するためのファストトラック法 | |
EP0311383B1 (fr) | Anticorps monoclonal de méthamphétamine, sa préparation, méthode d'essai et trousse d'essai de métamphétamine | |
US5106746A (en) | Process for the in vitro immunization of human splenocytes against tumor associated antigens | |
JP3219772B2 (ja) | アデノ随伴ウイルスcapタンパク質を特異的に認識するモノクローナル抗体 | |
JP3745411B2 (ja) | モノクローナル抗体 | |
JPH06321998A (ja) | 抗フモニシンモノクローナル抗体、ハイブリドーマ、ハプテン抗原及びその製造法 | |
JPH0789998A (ja) | 抗ミクロシスチンモノクローナル抗体およびそれを産生するハイブリドーマ | |
JPH01168299A (ja) | モノクローナル抗体およびそれを産生するハイブリドーマ | |
JP2840852B2 (ja) | C反応性蛋白質に対するモノクローナル坑体 | |
CA1270778A (fr) | Cellules hybrides secretant des anticorps anti- idiotypiques, anticorps monoclonaux secretes par lesdites cellules hybrides, leur preparation et leur application | |
EP0100734B1 (fr) | Procédé de séparation ou de purification d'un facteur favorisant le sommeil à partir d'un milieu biologique par une réaction immunologique du type antigène-anticorps | |
JPH08157500A (ja) | Fas抗原の定量法 | |
SU1527260A1 (ru) | Штамм гибридных культивируемых клеток животных MUS мUSсULUS, используемый дл получени моноклональных антител к @ - тимозину | |
JP3119311B2 (ja) | 酸化酵素活性を有するモノクローナル抗体 | |
JPH0433935A (ja) | ロドプシン薄膜とその作製方法 | |
JPS59226864A (ja) | トランスホ−ミンググロスファクタ−の酵素免疫測定法 | |
JP2593865B2 (ja) | ヒトファクターiに対する単クローン性抗体 | |
JPH07113000A (ja) | 抗ミンク成長ホルモンモノクローナル抗体及びハイブリドーマ | |
JPH0459879B2 (fr) | ||
JPH04190798A (ja) | モノクローナル抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997915542 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08952052 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2221893 Country of ref document: CA Ref country code: CA Ref document number: 2221893 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 533212 Kind code of ref document: A Format of ref document f/p: F |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1997915542 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997915542 Country of ref document: EP |